Primary open angle glaucoma and exfoliative glaucoma
Conditions
Interventions
Ripasudil eye drop is administrated twice daily until 3 months after surgery.
Brinzolamide eye drop is administrated twice daily until 3 months after surgery.
Sponsors
Faculty of Life Sciences, Kumamoto University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects are adult patients with primary open angle glaucoma or exfoliative glaucoma who approved as an indication for KDB-trabeculotomy at a preoperative conference and obtained the consent for this study in the document at the Kumamoto University Hospital and whose IOP after surgery is 12 mmHg or higher.
Exclusion criteria
Exclusion criteria: Exclusion criteria are cases who have difficulty obtaining consent for this study due to mental diseases, or reliable inspection data e.g. due to corneal diseases, who have a contraindication for Ripasuril and Brimonidine, and whose IOP is 20 mmHg or more at 1 day after surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of IOP at 1 day, 1 week, 1 month, and 3 months after surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual acuity, number and thickness of corneal endothelium, visual field, gonioscopy, doing condition and safety | — |
Countries
Japan
Contacts
Public ContactEri Takahashi
Faculty of Life Sciences, Kumamoto University Department of Ophthalmology
Outcome results
None listed